<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2018-13-170-173</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-2624</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Практика</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Practice</subject></subj-group></article-categories><title-group><article-title>Опыт применения фитотерапии при мочевых камнях инфекционного генеза</article-title><trans-title-group xml:lang="en"><trans-title>Experience in using phytotherapy for the treatment of infection-induced urinary stones</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Константинова</surname><given-names>О. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Konstantinova</surname><given-names>O. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., главный научный сотрудник отдела мочекаменной болезни</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яненко</surname><given-names>Э. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Yanenko</surname><given-names>E. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, ведущий специалист организационно-методического отдела</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Просянников</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Prosyannikov</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., зав. отделом мочекаменной болезни</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Катибов</surname><given-names>М. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Katibov</surname><given-names>M. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., зав. отделом общей и реконструктивной урологии</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НИИ урологии и интервенционной радиологии им. Н.А. Лопаткина – филиал ФГБУ «НМИЦ радиологии» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Lopatkin Research Institute of Urology and Interventional Radiology – branch of FSBI NMRRC of the Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>25</day><month>09</month><year>2018</year></pub-date><volume>0</volume><issue>13</issue><fpage>170</fpage><lpage>173</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Константинова О.В., Яненко Э.К., Просянников М.Ю., Катибов М.И., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Константинова О.В., Яненко Э.К., Просянников М.Ю., Катибов М.И.</copyright-holder><copyright-holder xml:lang="en">Konstantinova O.V., Yanenko E.K., Prosyannikov M.Y., Katibov M.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/2624">https://www.med-sovet.pro/jour/article/view/2624</self-uri><abstract><p>Одной из наиболее часто встречающихся форм мочекаменной болезни является фосфатный (инфекционного генеза) уролитиаз. Камни инфекционного генеза, как правило, рецидивируют, и пациенты с указанной формой – очень сложная категория больных мочекаменной болезнью, требующих постоянного наблюдения. Оно предполагает не только систематическое обследование, но и комплексное лечение. Целью исследования явилось определение влияния Фитолизина на инфекционно-воспалительный процесс и состояние обмена камнеобразующих веществ у пациентов с фосфатным (инфекционного генеза) уролитиазом.</p><sec><title>Материалы и методы</title><p>Материалы и методы. Обследовали 55 больных рецидивным фосфатным (инфекционного генеза) уролитиазом – 37 женщин и 18 мужчин в возрасте 31–68 лет. По данным биохимических методов обследования функциональное состояние печени и почек больных было в норме. В общем клиническом анализе мочи определяли лейкоцитурию у всех больных и в подавляющем большинстве случаев – кристаллурию фосфатов и трипельфосфатов. Бактериологический анализ мочи выявил бактериурию у всех больных. Диагностировали уреазопродуцирующие штаммы Ps. аeruginosa, Proteus mirabilis, Proteus vulgaris: титр составил от 104 до 106 КОЕ/мл. Подавляющая часть биохимических тестов выполнялась с помощью наборов химреактивов и автоматического анализатора «Labsystems», общий анализ мочи – на аппарате «Aution max Ax-4280» ис помощью световой микроскопии, бактериологический анализ мочи – общепринятым стандартным методом. Статистический анализ данных проводили с помощью t-критерия Стьюдента и результаты считали достоверными при уровне значимости р ≤ 0,05. Препарат применяли по 1 чайной ложке, разведенной в полстакана подслащенной воды, 3 раза в сутки после еды. Длительность 1 курса лечения Фитолизином колебалась в пределах 1–2 месяцев. Кроме Фитолизина, всем больным назначали диету, ограничивающую потребление цитрусовых, сухофруктов и продуктов с высоким содержанием камнеобразующих веществ или их предшественников, и прием жидкости не менее 2 л/сут. Влияние препарата на организм больных оценивали по 15 биохимическим показателям крови и мочи и по 3 показателям общего клинического анализа мочи. У больных с лейкоцитурией до 70 лейкоцитов в п/зр происходило ее снижение до 20–40 лейкоцитов в п/зр.</p></sec><sec><title>Результаты</title><p>Результаты. У больных с лейкоцитурией до 70 лейкоцитов в п/зр происходило ее снижение до 20–40 лейкоцитов в п/зр. Отмечено снижение рН мочи с 6,75 ± 0,29 до 6,44 ± 0,18 в 72,7% наблюдений. Кристаллурия фосфатов сохранялась, но превалировала кристаллурия кальция фосфатов (а не трипельфосфатов). Почечная экскреция мочевой кислоты увеличилась с 3,88 ± 0,14 до 4,46 ± 0,23 ммоль/сут в 83,6% случаев.</p></sec><sec><title>Выводы</title><p>Выводы. Установлено, что при применении Фитолизина функциональное состояние печени и почек оставалось в пределах нормы, без изменений. Выявлено уменьшение активности инфекционно-воспалительного процесса в мочевой системе. Не обнаружено влияния на метаболизм калия, натрия, кальция, неорганических фосфатов. Выявлено повышение почечной экскреции мочевой кислоты. </p></sec></abstract><trans-abstract xml:lang="en"><p>The phosphate (infection-induced) urolithiasis is one of the most common forms of urinary stone disease. Infection-induced urinary stones usually recur, and patients with this form is a very complicated category of patients with urolithiasis that requires constant monitoring. It involves not only a systematic examination, but also a comprehensive treatment. The study was aimed at evaluating the effect of phytolysin on the infectious inflammatory process and the metabolic stone-forming condition in patients with phosphate (infection-induced) urolithiasis.</p><sec><title>Materials and methods</title><p>Materials and methods. We examined 55 patients with recurrent phosphate (infection-induced) urolithiasis – 37 women and 18 men, age range 31–68 years. The biochemical examination showed that the functional state of the liver and kidneys of patients was normal. The common urine examination showed leukocyturia in all patients and phosphate crystalluria and triphyl phosphates in the vast majority of cases. The bacteriological urine analysis detected bacteriuria in all patients. Urease-producing strains Ps. aeruginosa, Proteus mirabilis, Proteus vulgaris were identified: the titre was 104 to 106 CFU/ml. The overwhelming majority of biochemical tests were performed using chemistry kits and Labsystems automatic analyzer; the common urine examination was performed using Aution Max Ax-4280 device and light microscopy, the bacteriological urine analysis was made by the common standard method. Statistical data analysis was carried out using Student’s t-test and the results were considered reliable at p-value ≤ 0.05. The drug was used at a dose of 1 teaspoon diluted in half a glass of sweetened water, 3 times a day after meals. The duration of 1 course of treatment with phytolysin ranged from 1 to 2 months. In addition to phytolysin, all patients were prescribed a diet that limited intake of citrus fruits, dried fruits and foods with a high content of stone-forming substances or their precursors, and a water intake of at least 2 litres/day. The effect of the drug on the patient’s condition was assessed using 15 blood and urine chemistry values and by 3 urine common examination values. The examination showed that 70 leukocytes per field in patients with leukocyturia decreased up to 20–40 leukocytes per field.</p></sec><sec><title>Results</title><p>Results. The examination showed that 70 leukocytes per field in patients with leukocyturia decreased up to 20–40 leukocytes per field. Urine pH A decreased from 6.75 ± 0.29 to 6.44 ± 0.18 in 72.7% of cases. Phosphate crystalluria persisted, but calcium crystallium phosphates (rather than triphyl phosphates) prevailed. Renal excretion of uric acid increased from 3.88 ± 0.14 to 4.46 ± 0.23 mmol/day in 83.6% of cases.</p></sec><sec><title>Conclusions</title><p>Conclusions. It was found that the use of phytolysin did not change the functional state of the liver and kidneys, which remained within the normal limits. The activity of the infectious-inflammatory process in the urinary system decreased. No effect on the metabolism of potassium, sodium, calcium, inorganic phosphates was detected. Renal excretion of uric acid was identified. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>мочекаменная болезнь</kwd><kwd>камни инфекционного генеза</kwd><kwd>консервативное лечение</kwd><kwd>инфекционно-воспалительный процесс</kwd><kwd>камнеобразующие вещества</kwd><kwd>экскреция мочевой кислоты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>urolithiasis</kwd><kwd>infection-induced stones</kwd><kwd>conservative treatment</kwd><kwd>infectious and inflammatory process</kwd><kwd>stone-forming substances</kwd><kwd>excretion of uric acid</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А.Д., Аполихин О.И., Сивков А.В., Солнцева Т.В., Комарова В.А. Анализ уронефрологической заболеваемости и смертности в Российской Федерации за период 2002–2014 гг. по данным официальной статистики. Экспе риментальная и клиническая урология, 2016. 4-12./ Kaprin AD, Apolikhin OI, Sivkov AV, Soln tseva TV, Komarova VA. Analysis of uronephrosiological morbidity and mortality in the Russian Federation in 2002 - 2014 according to official statistics. Experimentalnaya i Clinicheskaya Urologiya, 2016. 4-12.</mixed-citation><mixed-citation xml:lang="en">Kaprin AD, Apolikhin OI, Sivkov AV, Soln tseva TV, Komarova VA. Analysis of uronephrosiological morbidity and mortality in the Russian Federation in 2002 - 2014 according to official statistics. Experimentalnaya i Clinicheskaya Urologiya, 2016. 4-12.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Yasui T, Ando R, Okada A, Tozawa K, Iguchi M, Kohri K. Epidemiology of urolithiasis for improving clinical practice. Hinyokika Kiyo, 2012. 58, 12. 697-701.</mixed-citation><mixed-citation xml:lang="en">Yasui T, Ando R, Okada A, Tozawa K, Iguchi M, Kohri K. Epidemiology of urolithiasis for improving clinical practice. Hinyokika Kiyo, 2012. 58, 12. 697-701.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">C. Türk, T. Knoll, A. Petrik, K. Sarica, A. Skolarikos, M. Straub, C. Seitz. Guidelines on Urolithiasis. European Association of Urology, 2016.</mixed-citation><mixed-citation xml:lang="en">C. Türk, T. Knoll, A. Petrik, K. Sarica, A. Skolarikos, M. Straub, C. Seitz. Guidelines on Urolithiasis. European Association of Urology, 2016.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Константинова О.В. Прогнозирование и принципы профилактики мочекаменной болезни. Дисс. докт. мед. наук. М., 1999. 2 с. /Konstantinova OV. Prediction and principles of prevention of urolithiasis. Diss. of MD. M., 1999. 2 p.</mixed-citation><mixed-citation xml:lang="en">Konstantinova OV. Prediction and principles of prevention of urolithiasis. Diss. of MD. M., 1999. 2 p.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Яненко Э.К., Константинова О.В., Акулин С.М. Коралловидный нефролитиаз: методы оперативного лечения, осложнения и их профилактика. Урология, 2009, 6: 62-67. / Yanenko EK, Konstan tinova OV, Akulin SM. Dendritic nephrolithiasis: methods of surgical treatment, complications and their prevention. Urology, 2009, 6: 62-67.</mixed-citation><mixed-citation xml:lang="en">Yanenko EK, Konstan tinova OV, Akulin SM. Dendritic nephrolithiasis: methods of surgical treatment, complications and their prevention. Urology, 2009, 6: 62-67.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hesse AT, Tiselius H-G, Siener R et al. (Eds). Urinary Stones, Diagnosis, Treatment and Prevention of Recurrence. 3rd edn. Basel S., Karger AG, 2009.</mixed-citation><mixed-citation xml:lang="en">Hesse AT, Tiselius H-G, Siener R et al. (Eds). Urinary Stones, Diagnosis, Treatment and Prevention of Recurrence. 3rd edn. Basel S., Karger AG, 2009.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Pearle MS., Morgan MS.C. Medical management of renal stones.The BMJ 2016. 352–364.</mixed-citation><mixed-citation xml:lang="en">Pearle MS., Morgan MS.C. Medical management of renal stones.The BMJ 2016. 352–364.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Pearle MS, Lotan Y. Urinary lithiasis: etiology, epidemiology and pathogenesis. CampbellWalsh Urology, ninth edition; under general supervision Alan J. Wein. – Philadelphia, PA, 2007. 2. 1363-1392.</mixed-citation><mixed-citation xml:lang="en">Pearle MS, Lotan Y. Urinary lithiasis: etiology, epidemiology and pathogenesis. CampbellWalsh Urology, ninth edition; under general supervision Alan J. Wein. – Philadelphia, PA, 2007. 2. 1363-1392.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">His RS, Spieker AJ, Stoller ML, Jacobs JrDR., Reiner AP, McClelland RL et al. Coronary Artery Calcium Score and Association with Recurrent Nephro lithiasis: The Multi-Ethnic Study of Atherosclerosis. J Urol. 2016 April. 195(4 Pt 1). 971–976.</mixed-citation><mixed-citation xml:lang="en">His RS, Spieker AJ, Stoller ML, Jacobs JrDR., Reiner AP, McClelland RL et al. Coronary Artery Calcium Score and Association with Recurrent Nephro lithiasis: The Multi-Ethnic Study of Atherosclerosis. J Urol. 2016 April. 195(4 Pt 1). 971–976.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA, 2005. 293. 455.</mixed-citation><mixed-citation xml:lang="en">Taylor EN, Stampfer MJ, Curhan GC. Obesity, weight gain, and the risk of kidney stones. JAMA, 2005. 293. 455.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int, 2005. 68. 1230.</mixed-citation><mixed-citation xml:lang="en">Taylor EN, Stampfer MJ, Curhan GC. Diabetes mellitus and the risk of nephrolithiasis. Kidney Int, 2005. 68. 1230.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Filgueiras Pinto RD, Almeida JR., Kang C., Rosa ML, Lugon JR. Metabolic syndrome and associated urolithiasis in adults enrolled in a community-based health program. Fam Pract. 2012. 24.</mixed-citation><mixed-citation xml:lang="en">Filgueiras Pinto RD, Almeida JR., Kang C., Rosa ML, Lugon JR. Metabolic syndrome and associated urolithiasis in adults enrolled in a community-based health program. Fam Pract. 2012. 24.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Wojcikowski K, Stevenson L, Leach D, Wohlmuth H, Gobe G. Antioxidant capacity of 55 medicinal herbs traditionally used to treat the urinary system: a comparison using a sequential three-solvent extraction process..J. Altern Complement Med 2007 Jan-Feb. 13. 1. 103-9.</mixed-citation><mixed-citation xml:lang="en">Wojcikowski K, Stevenson L, Leach D, Wohlmuth H, Gobe G. Antioxidant capacity of 55 medicinal herbs traditionally used to treat the urinary system: a comparison using a sequential three-solvent extraction process..J. Altern Complement Med 2007 Jan-Feb. 13. 1. 103-9.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Машковский М.Д. Лекарственные средства. Пособие для врачей. 15-е изд., перераб., испр. и доп. М.: РИА «Новая волна»: Издатель Умеренков, 2008. 1206 с. /Mashkovskiy MD. Medicinal products. A guide for doctors. 15th ed., revised, corrected and added. M.: Novaya Volna RIA: Publisher Umerenkov, 2008. 1206 p.</mixed-citation><mixed-citation xml:lang="en">Mashkovskiy MD. Medicinal products. A guide for doctors. 15th ed., revised, corrected and added. M.: Novaya Volna RIA: Publisher Umerenkov, 2008. 1206 p.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Пакет компьютерных статистических программ SPSS./ SPSS computer statistical programs package.</mixed-citation><mixed-citation xml:lang="en">SPSS computer statistical programs package.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Eisner BH, Goldfarb DS, Pareek G. Pharmacologic treatment of kidney stone disease. .Urol Clin North Am, 2013. 40. 1. 21-30.</mixed-citation><mixed-citation xml:lang="en">Eisner BH, Goldfarb DS, Pareek G. Pharmacologic treatment of kidney stone disease. .Urol Clin North Am, 2013. 40. 1. 21-30.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Hussain M, Rizvi SA, Askari H, Sultan G, Lal M, Ali B, Naqvi SA. Management of stone disease: 17 years experience of a stone clinic in a developing country. J Pak Med Assoc., 2009. 59. 12. 843-846.</mixed-citation><mixed-citation xml:lang="en">Hussain M, Rizvi SA, Askari H, Sultan G, Lal M, Ali B, Naqvi SA. Management of stone disease: 17 years experience of a stone clinic in a developing country. J Pak Med Assoc., 2009. 59. 12. 843-846.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
